Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 100 participants.

Also called NCT06432452

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06432452
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT06432452. Randomized; triple masking; primary purpose treatment. Start 2024-11-11 (actual); primary completion 2026-06-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm
Acronym
EDIT-CAS
Condition
Coronary Spasm
Intervention (Drug)
Endothelin Receptor Antagonist
Intervention (Other)
Placebo control
Lead sponsor
Radboud University Medical Center (class: other)
Collaborator
UMC Utrecht (class: other)
Collaborator
Catharina Ziekenhuis Eindhoven (class: other)
Collaborator
Maasstad Hospital (class: other)

Record details

Record id
cardio:ct-nct06432452
Content hash
eda870963664cbbf32d872d9e699f0a56967461e61473ebf9566ac3273916a65